• 1
    Medsger TA Jr. Systemic sclerosis (scleroderma), eosinophilic fasciitis, and calcinosis. In: McCartyDJ, editor. Arthritis and allied conditions. Philadelphia: Lea and Febiger; 1985.
  • 2
    Thompson AE, Pope JE. Increased prevalence of scleroderma in southwestern Ontario: a cluster analysis. J Rheumatol 2002; 29: 186773.
  • 3
    Maini R, Zvaifler N. Rheumatoid arthritis and other synovial disorders. In: KlippelJ, DieppeP, editors. Rheumatology. Philadelphia: Mosby; 1998. Section 5: 2.16.
  • 4
    Ward MM. Prevalence of physician-diagnosed systemic lupus erythematosus in the United States: results from the third national health and nutrition examination survey. J Womens Health (Larchmt) 2004; 13: 7138.
  • 5
    Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999; 42: 1194203.
  • 6
    Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001; 44: 13518.
  • 7
    De la Mata J, Gomez-Sanchez MA, Aranzana M, Gomez-Reino JJ. Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases. Arthritis Rheum 1994; 37: 152833.
  • 8
    Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension [published erratum appears in N Engl J Med 2002;346:1258]. N Engl J Med 2002; 346: 896903.
  • 9
    Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364: 2639.
  • 10
    Scleroderma Clinical Trials Consortium. Membership information. URL:
  • 11
    JMP statistical software, version 4. Cary (NC): SAS Institute; 2000.
  • 12
    Van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996; 35: 36472.
  • 13
    Akesson A. Cyclophosphamide therapy for scleroderma. Curr Opin Rheumatol 1998; 10: 57983.
  • 14
    Calguneri M, Apras S, Ozbalkan Z, Ertenli I, Kiraz S, Ozturk MA, et al. The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis. Clin Rheumatol 2003; 22: 28994.
  • 15
    Mittal G, Udwadia Z, Joshi VR. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis [letter]. J Rheumatol 2003; 30: 11212.
  • 16
    Griffiths B, Miles S, Moss H, Robertson R, Veale D, Emery P. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 2002; 29: 23718.
  • 17
    Denton CP. Personal communication to Dr. Janet Pope, February 2005.
  • 18
    Thompson AE, Shea B, Welch V, Fenlon D, Pope J. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 2001; 44: 18417.
  • 19
    Janini SD, Scott DG, Coppock JS, Bacon PA, Kendall MJ. Enalapril in Raynaud's phenomenon. J Clin Pharm Ther 1988; 13: 14550.
  • 20
    Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, et al. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2000:CD000953.
  • 21
    Scorza R, Caronni M, Mascagni B, Berruti V, Bazzi S, Micallef E, et al. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon: a randomized, controlled study. Clin Exp Rheumatol 2001; 19: 5038.
  • 22
    Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004; 50: 398593.
  • 23
    Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI, et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) 2001; 40: 103843.
  • 24
    Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 7681.
  • 25
    Hong P, Pope JE, Ouimet JM, Rullan E, Seibold JR. Erectile dysfunction associated with scleroderma: a case-control study of men with scleroderma and rheumatoid arthritis. J Rheumatol 2004; 31: 50813.
  • 26
    Nowlin NS, Brick JE, Weaver DJ, Wilson DA, Judd HL, Lu JK, et al. Impotence in scleroderma. Ann Intern Med 1986; 104: 7948.
  • 27
    Simeon CP, Fonollosa V, Vilardell M, Ordi J, Solans R, Lima J. Impotence and Peyronie's disease in systemic sclerosis [letter]. Clin Exp Rheumatol 1994; 12: 464.
  • 28
    Lally EV, Jimenez SA. Impotence in progressively systemic sclerosis. Ann Intern Med 1981; 95: 1503.
  • 29
    Lally EV, Jimenez SA, Kaplan SR. Progressive systemic sclerosis: mode of presentation, rapidly progressive disease course, and mortality based on an analysis of 91 patients. Semin Arthritis Rheum 1988; 18: 113.
  • 30
    Ouimet JM, Pope J. Erectile dysfunction in men with scleroderma. Scleroderma Care Res 2004; 2: 149.
  • 31
    Benrud-Larson LM, Haythornthwaite JA, Heinberg LJ, Boling C, Reed J, White B, et al. The impact of pain and symptoms of depression in scleroderma. Pain 2002; 95: 26775.
  • 32
    Haythornthwaite JA, Heinberg LJ, McGuire L. Psychologic factors in scleroderma. Rheum Dis Clin North Am 2003; 29: 42739.
  • 33
    Matsuura E, Ohta A, Kanegae F, Haruda Y, Ushiyama O, Koarada S, et al. Frequency and analysis of factors closely associated with the development of depressive symptoms in patients with scleroderma. J Rheumatol 2003; 30: 17827.
  • 34
    Roca RP, Wigley FM, White B. Depressive symptoms associated with scleroderma. Arthritis Rheum 1996; 39: 103540.
  • 35
    Angelopoulos NV, Drosos AA, Moutsopoulos HM. Psychiatric symptoms associated with scleroderma. Psychother Psychosom 2001; 70: 14550.
  • 36
    Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 111923.
  • 37
    Denton CP, Black CM, for the 351 and BREATHE-1 Study Groups. Bosentan for scleroderma associated pulmonary arterial hypertension: a subgroup analysis of two placebo controlled trials [abstract]. Arthritis Rheum 2003; 48 Suppl 9: S456.
  • 38
    Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med 2000; 132: 42534.
  • 39
    Oudiz RJ, Schilz RJ, Barst RJ, Galie N, Rich S, Rubin LJ, et al, and the Treprostinil Study Group. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 2004; 126: 4207.
  • 40
    Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, et al, and the Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 3229.